The Importance of Oral Health for HIV Patients
One under-the-radar issue HIV patients might underestimate is the fragility of their oral health. It’s an important factor that warrants attention. Before antibodies appear, the mouth is the first part of the body that shows signs of carrying the infection. Catching the virus at such an early stage leads to earlier treatment and helps prevent the spreading of HIV to another partner.
It’s prudent for HIV patients to practice good oral health care. Proper hygiene and regular checkups with a dentist can make a world of difference. If you’re wondering what potential drawbacks poor hygiene in this body part may cause, here are some of the most common.
The Most Common Oral Health Side-Effects for HIV Patients
Of the many side-effects that come with having HIV, candidiasis (also known as thrush) is among the most common. Candidiasis can cause difficulty swallowing, a decreased appetite, and painful areas in the mouth.
Another potential red flag to look out for is hairy leukoplakia. Visible symptoms of hairy leukoplakia are white patches that form around the tongue. These patches are permanent. Regular oral health tools can’t remove them.
Oral health concerns of this ilk should not go ignored. If matters are left to linger, and if eating causes enough pain, these ailments have the potential to cause malnutrition. It can also influence how your body absorbs HIV medication.
Take Preventative Steps
HIV patients are more susceptible to infection, pain and tooth loss for a variety of reasons. But they’re still easily preventable problems if paid attention to early and often. Now that oral surgeons are noting the importance their field has in early detection, awareness could become more commonplace. Even small-scale measures, like brushing your teeth twice daily and flossing, will help you avoid most routine mouth problems. It’s another necessary aspect of living with HIV.
How HIV Affects Tuberculosis Bacterium
Most people know that HIV negatively impacts the immune system, crippling the body’s ability to fight off infections. The key to fighting the virus is to find out how it infiltrates the immune system. New research has made some developments into HIV and tuberculosis bacterium (MTB).
The Danger of Tuberculosis Bacterium
Tuberculosis bacterium (MTB) is the bacteria that causes tuberculosis to occur. Normally, the immune system prevents this infection by enclosing the bacteria in scar tissue. It is due to this special defense that only around 10 percent of people with “latent” tuberculosis develops the condition. However, if a patient is infected with HIV, they are at a greater risk of contracting the disease.
How Doctors Are Using Research to Develop a Vaccine
When the researchers at the Linköping University in Sweden discovered the connection between HIV and tuberculosis bacterium, they wanted to know more. They first started their inquiry by examining dendritic cells. These cells are a crucial aspect of the immune system, breaking down the bacteria. The body’s T-cells then kills the leftover pieces of bacteria before it has a chance to harm the body any further.
HIV inhibits the dendritic and T-cells. While most research has only proved that the virus affects T-cells, its interaction with dendritic cells is a new development.
“We have now shown that HIV has a clear effect also on the innate immune defense, in particular, the dendritic cells, which link the innate and the adaptive immune defenses. Much work remains to be done, but we can already suggest that one important future treatment strategy for infection should be to find ways to strengthen or boost cells in the immune defense using what is known as ‘host-directed therapy’,” says study lead Robert Blomgran.
Tuberculosis is a disease that mainly affects the lungs, making life difficult. Hopefully, that vaccine can be developed, so that HIV patients can be better protected.
Nanotechnology and HIV Drug Therapies
Nanotechnology sounds like science fiction. However, it is very real, and scientists are manipulating matter on an atomic, molecular, and supramolecular scale in order to achieve great things. One prime example is the development of HIV drug therapies. In a research study by the University of Liverpool, they sought to improve how HIV drugs are delivered to patients.
The Problem With HIV Drugs
HIV is a serious disease. It requires powerful medicine in order to combat its effects. Unfortunately, the drugs used to combat the virus need to be taken daily. This can be difficult for many patients. Keeping up with their regimen requires sticking to an intense schedule and remembering to take pills. Some even quit taking the drugs because of how demanding the therapy is.
With Solid Drug Nanoparticle (SDN) technology, scientists hope to improve HIV drugs. HIV patients want better drugs. Theoretically, this technology should make it easier for their bodies to absorb them. If successful, this form of nanotechnology would reduce the number or doses that HIV patients have to take, and possibly save them money.
Making Nanotechnology Applicable
Nanotechnology is still a relatively new field, which means that it is going to take some time to develop. Even worse, this type of medicine isn’t readily available to HIV patients. Currently, the University of Liverpool is developing a novel water dispersible nanotherapy for a poorly soluble antiretroviral medicine called lopinavir. It is still in the testing phase; however, some are hopeful of its success.
Research leader and Pharmacologist Professor Andrew Owen says “The fruits of our interdisciplinary research are beginning to be realized. Our approach has the potential to overcome challenges with current antiretroviral therapy, which include administration of high doses needed to achieve efficacious concentrations in the body, and the urgent need for better formulations for children living with HIV.”
Many Gay Men Are Unaware of HIV Prevention Methods
HIV vaccines are important. However, people should not ignore HIV prevention methods. Preventing HIV is a crucial part of protecting yourself. Medical treatments act as a means of protection. However, a study has found that many gay men do not know about the HIV prevention methods that are available.
Gay Men and HIV
Gay and bisexual men have been at risk for HIV for many years. In 2013, the CDC estimated that “Gay, bisexual, and other men who have sex with men made up an estimated 2% of the population but 55% of people living with HIV in the United States.” This is a startling statistic.
With HIV so widespread among the gay community, these men are more likely to contract the disease. The higher rates of HIV are more than likely due to many gay men having multiple partners and practicing anal sex. Unfortunately, this community has a hard road ahead when it comes to decreasing the number of men with this disease. Scientists are constantly researching new methods of preventions and vaccines to help them.
Knowledge Is Power: Knowing Which HIV Prevention Methods Can Protect You
The John Hopkins Bloomberg School of Public Health found that only 4 in 10 gay and bisexual men in Baltimore – who did not have HIV – are not aware that pre-exposure prophylaxis medication (PrEP) is an effective HIV prevention method.
Pre-exposure prophylaxis medication (PrEP) is a pill that is taken daily to prevent the contraction of the disease. It contains two HIV medication in one pill. For those who take this medication as prescribed, PrEP is known to be 92% effective at preventing infections in men.
HIV prevention methods are an important part of stopping the spread of the disease within the gay community. The researchers tested men in Baltimore because the number of HIV incidents in the state among gay and bisexual men was estimated to be 31 percent in 2011. Their findings suggest that doctors are not presenting the medication to their patients.
According to study leader Julia R. G. Raifman, ScD, a post-doctoral fellow in the Bloomberg School’s Department of Epidemiology, “Doctors have limited time with their patients, but with gay and bisexual male patients, physicians definitely need to make it a point to discuss HIV risks and whether PrEP is a good option.”
Age Affects HIV Treatments in Individuals
HIV affects many people in the United States, and finding the right HIV treatments is difficult. A new article, published in the Journal of the American Geriatrics Society, suggests that age affects treatment for elderly patients. New age-specific strategies need to be developed to combat the virus.
Age and HIV
Unfortunately, a certain percentage of young people in America have contracted HIV. According to the CDC, in 2012, around 44% of young people around the age of 18 to 24 years old were living with HIV they did not know they had. Even more frightening is the fact that by 2014, young people around the age of 13 to 24 years old made up more than 1 in 5 new HIV diagnosis.
Meanwhile, the elderly are at risk too. Older adults aged 55 and older, account for at least 26% of the estimated 1.2 million people living with HIV. This group, in particular, is at a greater risk. They have the same risk factors as younger people, but they are less aware of what can cause HIV.
Developing Age-Specific HIV Treatments
Since many older adults are less aware of HIV risk factors, they have an increased risk for late or missed diagnosis. Even worse, they are more susceptible to disease, meaning drugs carry more side effects for them. Researchers began investigating based on the need for elderly patients to receive proper HIV treatments.
“Our article highlights the need for more research on screening, evaluation, and treatment in older adults infected with HIV. As the number of older people living with HIV grows, we need scientifically sound data to help prepare our clinicians and healthcare systems for the unique needs and expectations of this group,” said Dr. Aroonsiri Sangarlangkarn, co-author of the Journal of the American Geriatrics Society article.
Hopefully, physicians will see this research as a means to find better HIV treatments for older adults. Using the right tools can help with diagnosing these patients and helping them live with the disease.